By helping Hispanic patients interact effectively with the health-care system, ob/gyns can increase the amount of prenatal care these women receive and decrease their high rates of preterm delivery and pregnancy-related maternal mortality.
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More